OncoMatch

OncoMatch/Clinical Trials/NCT06424340

MB-dNPM1-TCR.1 in Relapsed/Refractory AML

Is NCT06424340 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies MB-dNPM1-TCR.1 for leukemia, myeloid, acute.

Phase 1/2RecruitingMiltenyi Biomedicine GmbHNCT06424340Data as of May 2026

Treatment: MB-dNPM1-TCR.1The goal of this Phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leukocyte antigen (HLA) A\*02:01 in patients with relapsed or refractory AML.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Biomarker criteria

Required: NPM1 mutation recognized by dNPM1-TCR.1

AML has NPM1 mutation which is recognized by dNPM1-TCR.1 and for which a specific Q-PCR is available for disease monitoring.

Required: HLA-A A*02:01 (positive)

Positive for HLA-A*02:01 according to genotyping results.

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

Min 2 prior lines

Must have received: intensive chemotherapy or decitabine or other standard therapy (intensive chemotherapy, decitabine)

No morphological CR after at least two courses of intensive chemotherapy, decitabine or other standard therapy

Lab requirements

Blood counts

Number of circulating WBC above 1x10^9/L with less than 20% leukemic blasts and at least 0.3x10^9 T cells/L and 0.03 x 10^9 CD8+ T cells/L.

Kidney function

Serum creatinine < 2.0 × ULN and eGFR ≥ 30 mL/min calculated according to the modified MDRD formula.

Number of circulating WBC above 1x10^9/L with less than 20% leukemic blasts and at least 0.3x10^9 T cells/L and 0.03 x 10^9 CD8+ T cells/L. Serum creatinine ≥ 2.0 × ULN or eGFR < 30 mL/min calculated according to the modified MDRD formula [excluded].

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify